Polyrizon Signs MOU to Acquire 51% Stake in Arrow Aviation
Polyrizon recently announced the signing of a non-binding Memorandum of Understanding with Arrow Aviation, a global private aviation company. Under the terms of the MOU, Polyrizon intends to acquire a 51% stake in Arrow Aviation on a fully diluted basis through a cash investment of approximately $5.8M, marking a strategic expansion into the high-growth private aviation sector. Arrow Aviation has annual unaudited revenues of approximately $19M and adjusted EBITDA of approximately $3M. The proposed transaction includes ancillary arrangements, such as the transfer of a Hawker 800 aircraft valued at $3.5M to Arrow Aviation by a third party, in exchange for a convertible note (convertible in Polyrizon ordinary shares) issued by Polyrizon. Additionally, existing Arrow Aviation shareholders will forgive outstanding shareholder debts owed by Arrow Aviation in return for convertible notes (convertible in Polyrizon ordinary shares) from Polyrizon, enabling Arrow Aviation to emerge debt-free from institutional obligations post-closing. The MOU also outlines mutual call and put options on the remaining 49% of Arrow Aviation's shares, exercisable after two years, based on agreed valuation multiples tied to financial metrics like EBITDA or revenue, which may result in Polyrizon acquiring 100% of Arrow Aviation on a fully diluted basis. The signing of a definitive agreement is expected to occur within 30 days of the MOU, subject to due diligence, after which the closing of the acquisition would be expected to occur following the satisfaction of customary closing conditions.
Trade with 70% Backtested Accuracy
Analyst Views on PLRZ
About PLRZ
About the author

- Technological Innovation: Polyrizon's Capture&Contain™ platform utilizes proprietary polysaccharide formulations to rapidly form a protective biophysical layer on the nasal mucosa, addressing emerging respiratory virus threats, particularly in the early stages before vaccines and therapeutics are developed.
- Laboratory Study Results: Controlled in-vitro studies demonstrate that this technology can effectively limit viral-host interactions across multiple respiratory virus families, such as influenza and coronaviruses, with treated cell cultures showing better cell viability, supporting its potential effectiveness.
- Market Demand: As the world faces increasingly frequent viral outbreaks, Polyrizon's technology is viewed as a fast, adaptable non-specific protection measure that could become a strategic asset for governments and healthcare systems in enhancing resilience against future threats.
- Investment Opportunity: Although the Capture&Contain™ platform is still in pre-clinical stages, its differentiated opportunity in pandemic preparedness and respiratory protection may present an attractive market prospect for investors.
- Technological Innovation: Polyrizon is advancing its Capture&Contain™ platform, which utilizes proprietary polysaccharide formulations to create a protective biophysical layer on the nasal mucosa, aimed at addressing emerging respiratory virus threats, particularly Hantavirus and novel coronavirus variants.
- Market Demand: With the rise of Hantavirus cluster cases, there is an increasing global need for broad-spectrum protective solutions, and Polyrizon's technology can provide immediate defense before pathogen-specific vaccines and therapeutics are developed, thereby reducing public health risks.
- Laboratory Validation: Laboratory studies conducted under controlled in-vitro conditions demonstrate that this technology can effectively limit viral-host interactions across multiple respiratory virus families, with treated cell cultures showing better preservation of cell viability, supporting its potential effectiveness.
- Strategic Positioning: Polyrizon's PL-16 product candidate, based on the Capture&Contain™ technology, while still in pre-clinical stages, may represent a differentiated opportunity in the rapidly growing field of pandemic preparedness and respiratory protection, aligning with the global demand for fast, adaptable protective technologies.
- Patent Application Progress: Polyrizon has filed a divisional patent application with the European Patent Office for its Trap & Target (T&T) platform, aimed at protecting its advanced intranasal drug delivery system, thereby enhancing drug efficacy and prolonging residence time in the nasal cavity.
- Technological Innovation: The T&T platform addresses critical challenges in local and systemic drug delivery by improving the bioavailability of active pharmaceutical ingredients, which is expected to significantly enhance respiratory health and drug delivery effectiveness.
- Market Potential: The platform's design includes features such as prolonged residence time, improved bioavailability, and controlled release, making it suitable for a wide range of drug types and offering extensive therapeutic application potential.
- Strategic Significance: CEO Tomer Izraeli emphasized that this patent application marks an important step in strengthening the global intellectual property portfolio, demonstrating the company's commitment to addressing healthcare challenges through innovative technology and improving patient outcomes.
- Financing Overview: Polyrizon Ltd. has successfully closed a registered direct offering and concurrent private placement with a single institutional investor, raising approximately $3.5 million, indicating strong market confidence in its biotechnology solutions.
- Unit Issuance Details: The transactions involved the issuance of 388,888 Units, each comprising one Ordinary Share and one Common Warrant, at a combined offering price of $9.00 per Unit, reflecting investor confidence in the company's future growth potential.
- Use of Proceeds: The company intends to utilize the net proceeds along with existing cash for general corporate purposes and working capital, aiming to support further development and market introduction of its innovative medical devices.
- Market Outlook: With the total number of Ordinary Shares reaching 2,083,939, Polyrizon's financing will provide essential funding to bolster its advancements in intranasal drug delivery technology within the rapidly evolving biotechnology sector.
- Financing Agreement: Polyrizon Ltd. announced a definitive agreement for a $3.5 million registered direct offering and concurrent private placement, aimed at bolstering its cash position to support upcoming clinical milestones for its proprietary intranasal therapies.
- Clinical Development Strategy: The company has signed an agreement with a leading global preclinical CRO, with studies anticipated to begin in Q2 2026, marking a significant step toward clinical validation and advancing the development of intranasal protective gels.
- Pipeline Expansion: Polyrizon's pipeline includes intranasal protective gels for viral defense and allergen prevention, with management emphasizing that this financing provides essential resources for advancing these programs and transitioning into clinical development, showcasing the company's commitment to innovation in respiratory and allergy care.
- Stock Split Impact: The company implemented a 1-for-6 reverse stock split on November 24, 2025, with PLRZ currently trading at $11.50, down 6.64%, reflecting market attention on its financing and future development prospects.
- Strong Cash Position: As of December 31, 2025, Polyrizon reported approximately $17.5 million in cash and cash equivalents, ensuring financial flexibility for future clinical trials and R&D initiatives.
- Significant FDA Progress: The company completed a productive FDA Pre-Submission Meeting for the PL-14 (NASARIX™) Allergy Blocker, discussing clinical development strategies and potential human trials, marking a crucial step towards clinical phase advancement.
- Clinical Material Production: Polyrizon signed an agreement with Eurofins CDMO to initiate GMP manufacturing of Clinical Trial Material, preparing for U.S. clinical studies expected to commence in Q2 2026, thereby enhancing its operational readiness.
- Diversified Investment Exploration: The company announced initiatives to explore potential revenue-generating investment opportunities in high-growth sectors, including private aviation and advanced eVTOL drone technologies, demonstrating a proactive approach to diversification while maintaining financial flexibility.








